SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较

doi:10.11904/j.issn.1002-3070.2017.01.005

实用肿瘤学杂志 ›› 2017, Vol. 31 ›› Issue (1): 23-30.doi: 10.11904/j.issn.1002-3070.2017.01.005

SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较

陈力¹, 张玉新¹, 左艳娇¹, 马菲², 宋洪江¹, 薛英威¹

1.哈尔滨医科大学附属肿瘤医院胃肠外科(哈尔滨 150081);
2.哈尔滨医科大学附属肿瘤医院腔镜室

收稿日期:2016-10-19 出版日期:2017-02-28 发布日期:2017-02-20
通讯作者: 宋洪江,E-mail:hongjiangsong2015@163.com
作者简介:陈力,男,(1990-),硕士研究生,从事胃肠道肿瘤的临床与基础研究
基金资助:
吴阶平基金科学技术部(320.6750.13105);黑龙江省教育厅面上项目(12541458)

The comparison of clinical efficacy of SOX and XELOX in the neoadjuvant chemotherapy for advanced gastric carcinoma

CHEN Li¹, ZHANG Yuxin¹, ZUO Yanjiao¹, MA Fei², SONG Hongjiang¹, XUE Yingwei¹

1.Department of Gastrointestinal Surgery,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081,China;
2.Department of Endoscopy,The Affiliated Tumor Hospital of Harbin Medical University

Received:2016-10-19 Online:2017-02-28 Published:2017-02-20

摘要/Abstract

摘要： 目的探讨SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效。方法选取2011年2月1日—2015年10月1日我院行SOX和XELOX新辅助化疗的胃癌患者75例。分析两种方案临床分期、疗效评价、手术情况、术后病理、不良反应、生存分析等情况。结果 SOX和XELOX有效率分别为47.22%和41.03%。两组在CT疗效评价、有效率、疾病控制率方面比较,差异均不具有统计学意义(P＞0.05);两组DFS、OS中位生存时间,差异均具有统计学意义(P＜0.05)。结论 SOX和XELOX对进展期胃癌进行新辅助化疗均具有较高的安全性和有效性,XELOX远期疗效要优于SOX,改善患者预后。

关键词: 新辅助化疗, 进展期胃癌, 有效率, 无病生存时间, 总生存时间

Abstract: Objective To investigate the clinical efficacy of SOX and XELOX in neoadjuvant chemotherapy for advanced gastric carcinoma.Methods Seventy-five cases with advanced gastric carcinoma were selected from our hospital from Feb 1,2011 to Oct 1,2015.SOX and XELOX were used to these patients treatment.The relationship between SOX and XELOX with tumor stage,clinical curative effect evaluation,operation,postoperative pathology,adverse reaction,survival analysis with advanced gastric carcinoma had been analyzed retrospectively.Results The efficacy of SOX and XELOX were 47.22%,41.03%.Compared with the two groups,the CT curative effect evaluation,effective rate,disease control rate had no significant differences(P＞0.05).The median survival time of DFS and OS were significant between the two groups(P＜0.05).Conclusion The SOX and XELOX for neoadjuvant chemotherapy of advanced gastric carcinoma treatment is safety and effective,and the XELOX is better than SOX in terms of long-term effect,prognosis and clinical benefits.

Key words: Neoadjuvant chemotherapy, Advanced gastric carcinoma, Effective rate, Disease free survival, Overall survival

中图分类号:

R735.2

陈力, 张玉新, 左艳娇, 马菲, 宋洪江, 薛英威. SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较[J]. 实用肿瘤学杂志, 2017, 31(1): 23-30.

CHEN Li, ZHANG Yuxin, ZUO Yanjiao, MA Fei, SONG Hongjiang, XUE Yingwei. The comparison of clinical efficacy of SOX and XELOX in the neoadjuvant chemotherapy for advanced gastric carcinoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 23-30.

参考文献

1 Rebecca LS,Kimberly DM,Ahmedin J,et al.Cancer Statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.
2 Strong VE,Wu AW,Selby LV,et al.Differences in gastric cancer survival between the U.S.and China[J].J Surg Oncol,2015,112(1):31-37.
3 Marrelli D,Polom K,de Manzoni G,et al.Multimodal treatment of gastric cancer in the west:where are we going?[J].World J Gastroenterol,2015,21(26):7954-7969.
4 Fontana E,Smyth EC.Novel targets in the treatment of advanced gastric cancer:a perspective review[J].Ther Adv Med Oncol,2016,8(2):113-125.
5 Tian SB,Yu JC,Kang WM,et al.Effect of neoadjuvant chemotherapy treatment on prognosis of patients with advanced gastric cancer:a retrospective study[J].Chin Med Sci J,2015,30(2):84-89.
6 Tao F,Bu ZD,Li ZY,et al.Neoadjuvant chemoradiation therapy for resectable esophago gastric adenocarcinoma:a meta-analysis of randomized clinical trials[J].BMC Cancer,2015,15:322-331.
7 Wang X,Wang ML,Zhou LY,et al.Randomized phaseⅡstudy comparing paclitaxel with S-1 vs.S-1 as first-line treatment in patients with advanced gastric cancer[J].Clin Transl Oncol,2013,15:836-842.
8 Bang YJ,Kim YW,Yang HK,et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):a phase 3 open-label,randomised controlled trial[J].Lancet,2012,379(9813):315-321.
9 Knight G,Earle CC,Cosby R,et al.Neoadjuvant or adjuvant therapy for resectable gastric cancer:a systematic review and practice guideline for North America[J].Gastric Cancer,2013,16:28-40.
10 Ba-Ssalamah A,Prokop M,Uffnann M,et al.Dedicated multidetector CT of the stamach spectrum of diseases[J].Radio Graphics,2003,23(3):625-645.
11 Yoshikawa T,Tanabe K,Nishikawa K,et al.Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy:cohort evaluation within a randomized phase II study[J].Ann Surg Oncol,2014,21(Suppl 3):385-389.
12 Oh SY,Kwon HC,Jeong SH,et al.A phase Ⅱ study of S-1 and oxaliplatin(SOX)combination chemotherapy as a first line therapy for patients with advanced gastric cancer[J].Invest New Drugs,2012,30(1):350-356.
13 Luo HY,Xu RH,Wang F,et al.Phase Ⅱ trial of XELOX as first-line treatment for patients with advanced gastric cancer[J].Chemotherapy,2010,56(2):94-100.
14 Aoyama T,Yoshikawa T,Watanabe T,et al.Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients[J].Gastric Cancer,2012,15(1):76-82.
15 Tang L,Li ZY,Li ZW,et al.Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT:a comparison with pathological regression[J].Clinical Radiology,2015,70:1198-1204.
16 Koizumi W,Takiuchi H,Tsuburaya Y,et al.PhaseⅡstudy of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer(G-SOX study)[J].Ann Oncol,2010,21(5):1001-1005.
17 李涛,冯道夫,梁美霞,等.进展期胃癌应用SOX方案新辅助化疗对肿瘤TNM分期的影响[J].世界华人消化杂志,2014,22(2):249-252.
18 肖康,戈伟.奥沙利铂联合卡培他滨的新辅助化疗治疗进展期胃癌的疗效及安全性[J].中国肿瘤临床与康复,2016,23(3):261-263.
19 靖昌庆,李乐平,王金中.XELOX和FOLFOX4新辅助化疗方案对不能手术切除的局部进展期胃癌的疗效比较[J].中华消化外科杂志,2010,9(6):430-433.
20 张剑军,郑志超,赵岩,等.FOLFOX、XELOX、SOX 方案用于局部进展期胃腺癌的疗效及安全性比较[J].山东医药,2014,54(33):44-45.
21 Zhu YP,Sheng LL,Wang L,et al.Clinical efficacy of oxaliplatin combined with capecitabine(XELOX)and oxaliplatin combined with S-1(SOX)on advanced gastric cancer[J].Cancer Res Prev Treat,2014,41(7):815-819.
22 李远军,邢娟,吴翰昌,等.奥沙利铂联合替吉奥(SOX)与奥沙利铂联合卡培他滨(XELOX)治疗中国进展期胃癌患者的Meta 分析[J].中国生化药物杂志,2015,5(35):57-60.

[1]	张宝综述, 郑志超校审. 进展期胃癌淋巴结清扫研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 78-81.
[2]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[3]	张锡,陈力,薛英威. 外周血中CEA和CA19-9的表达水平在进展期胃癌中的预后价值[J]. 实用肿瘤学杂志, 2017, 31(4): 342-347.
[4]	戴猛, 李锐, 刘贵庭, 梁金龙, 冯金发, 徐善勇. 新辅助化疗后保留乳房手术治疗进展期乳腺癌可行性分析[J]. 实用肿瘤学杂志, 2016, 30(2): 109-113.
[5]	巴志昌, 王欣欣, 崔万辉, 国飞, 张修石. MRI弥散加权成像对宫颈癌新辅助化疗评估的应用价值[J]. 实用肿瘤学杂志, 2015, 29(6): 518-522.
[6]	朱宏, 朱莉, 韩世愈, 方芳, 于洋. 磁共振弥散加权成像对宫颈癌新辅助化疗后无进展生存期的预测价值[J]. 实用肿瘤学杂志, 2014, 28(6): 519-523.
[7]	宁四清, 詹波涛, 徐海声. TNP方案在头颈部鳞状细胞癌中的疗效探讨[J]. 实用肿瘤学杂志, 2014, 28(6): 540-544.
[8]	宋雨霖综述, 王晶审校. 卵巢癌术前新辅助化疗筛选与评估的展望[J]. 实用肿瘤学杂志, 2014, 28(6): 553-556.
[9]	马荣, 陈曦海, 耿晓星, 刘爽, 张恒. 术前同期放化疗对局部晚期宫颈癌近期疗效的综合评价[J]. 实用肿瘤学杂志, 2012, 26(4): 314-318.
[10]	许亚晔, 陈学发, 李秀娟, 周振寿. 螺旋CT扫描对进展期胃癌浸润深度的研究[J]. 实用肿瘤学杂志, 2012, 26(2): 146-149.
[11]	滕冲, 宋晓薇, 蔡莉. Ki-67在乳腺癌新辅助化疗中的作用及临床意义[J]. 实用肿瘤学杂志, 2012, 26(2): 188-192.
[12]	刘扬, 庞达. 乳腺癌新辅助化疗前后Ki-67、HER-2、ER和PR的变化与临床缓解率的关系[J]. 实用肿瘤学杂志, 2011, 25(5): 442-445.
[13]	张一君, 邹天宁, 陈杨萍, 陈艳. 乳腺癌新辅助化疗疗效评价及预测的研究进展[J]. 实用肿瘤学杂志, 2011, 25(5): 477-481.
[14]	印明柱, 娄阁, 陈秀玮, 顾泰华. 新辅助化疗后根治性手术与同步放化疗在局部晚期宫颈癌的远期疗效评价^△[J]. 实用肿瘤学杂志, 2011, 25(1): 40-45.
[15]	张斌. 乳腺癌新辅助化疗应该注意的几个问题[J]. 实用肿瘤学杂志, 2010, 24(6): 502-505.

SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较

The comparison of clinical efficacy of SOX and XELOX in the neoadjuvant chemotherapy for advanced gastric carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价